A biotech with a yen for pricey rare disease drugs — and bargain basement shopping — adopts another orphan in latest M&A pact
After making it through a long, painful haul to get past a CRL and on to an FDA approval last summer, little Chiasma has found a buyer.
Amryt $AMYT, a company known for its appetite for acquiring expensive drugs for rare diseases at bargain prices, snagged Chiasma and its acromegaly drug Mycapssa (octreotide) capsules in an all-stock deal — with an exchange of 0.396 shares of Amryt for every share of Chiasma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.